Compounds > dq113
Page last updated: 2024-12-08

dq113

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

DQ113: a potent quinolone, effective against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus and methicillin-susceptible and -resistant coagulase-negative staphylococci; formerly referred to as D61-1113 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID493409
CHEMBL ID7265
SCHEMBL ID6206229
MeSH IDM0426436

Synonyms (15)

Synonym
dq-113
3-quinolinecarboxylic acid, 5-amino-7-[(3r,4s)-3-(1-aminocyclopropyl)-4-fluoro-1-pyrrolidinyl]-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-1,4-dihydro-8-methyl-4-oxo-
5-amino-7-[(3r,4s)-3-(1-aminocyclopropyl)-4-fluoro-pyrrolidin-1-yl]-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-8-methyl-4-oxo-quinoline-3-carboxylic acid
dq113
CHEMBL7265
5-amino-7-[(3r,4s)-3-(1-aminocyclopropyl)-4-fluoropyrrolidin-1-yl]-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-8-methyl-4-oxoquinoline-3-carboxylic acid
SCHEMBL6206229
190954-07-5
5-amino-7-[(3s,4r)-4-(1-aminocycloprop-1-yl)-3-fluoropyrrolidin-1-yl]-6-fluoro-1-[(1r,2s)-2-fluorocycloprop-1-yl]1,4-dihydro-8-methyl-4-oxo-quinoline-3-carboxylic acid
unii-9f4x7r2jpx
3-quinolinecarboxylic acid, 5-amino-7-(3-(1-aminocyclopropyl)-4-fluoro-1-pyrrolidinyl)-6-fluoro-1-(2-fluorocyclopropyl)-1,4-dihydro-8-methyl-4-oxo-, (3r-(1(1r*,2s*),3alpha,4alpha))-
5-amino-7-((3r,4s)-3-(1-aminocyclopropyl)-4-fluoro-pyrrolidin-1-yl)-6-fluoro-1-((1r,2s)-2-fluorocyclopropyl)-8-methyl-4-oxo-quinoline-3-carboxylic acid
d61-1113
9f4x7r2jpx ,
3-quinolinecarboxylic acid, 5-amino-7-(3-(1-aminocyclopropyl)-4-fluoro-1-pyrrolidinyl)-6-fluoro-1-(2-fluorocyclopropyl)-1,4-dihydro-8-methyl-4-oxo-, (3r-(1(1r*,2s*),3.alpha.,4.alpha.))-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (71)

Assay IDTitleYearJournalArticle
AID285289Effect on 32 ug/ml ciprofloxacin-selected penicillin-resistant Streptococcus pneumoniae 334 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID285309Susceptibility of vancomycin-resistant Enterococcus species single-step mutant by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID285305Effect on 2 ug/ml moxifloxacin-selected penicillin-resistant Streptococcus pneumoniae 218 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID285294Effect on 4 ug/ml levofloxacin-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID285307Effect on 16 ug/ml ciprofloxacin-selected penicillin-resistant Streptococcus pneumoniae 218 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID208626Antibacterial activity was determined against clinically isolated penicillin resistant Streptococcus pneumoniae (PRSP) strains (50 strains)2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID12719Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID285303Effect on 0.06 ug/ml DQ113-selected penicillin-resistant Streptococcus pneumoniae 218 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID285291Effect on 0.06 ug/ml DQ113-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID285290Susceptibility of penicillin-resistant Streptococcus pneumoniae 216 by by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID12718Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID209591Antibacterial activity was determined against Streptococcus mitis IID685 strain after incubation at 37 degrees C for 18 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID285281Effect on 1 ug/ml moxifloxacin-selected penicillin-resistant Streptococcus pneumoniae 335 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID206629Antibacterial activity was determined against clinically isolated Levofloxacin-methicillin resistant Staphylococcus aureus (LVFX-r MRSA) strains (74 strains)2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID211826Mortality was determined after 50 mg/kg dose administered intravenously to 5-week old male mice at a speed of 0.2 mL/min counted on day 7 for total 2 mice; NT= Not tested2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID21957Solubility was determined in water2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID285293Effect on 2 ug/ml moxifloxacin-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID285288Effect on 4 ug/ml levofloxacin-selected penicillin-resistant Streptococcus pneumoniae 334 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID12296Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID206214Antibacterial activity was determined against Staphylococcus epidermis 56500 strain after incubation at 37 degrees C for 18 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID12717Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID285306Effect on 16 ug/ml levofloxacin-selected penicillin-resistant Streptococcus pneumoniae 218 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID12293Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID285283Effect on 16 ug/ml ciprofloxacin-selected penicillin-resistant Streptococcus pneumoniae 335 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID66576Antibacterial activity was determined against clinically isolated vancomycin-A resistant enterococci (VRE) strains (33 strains)2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID206650Antibacterial activity was determined against clinically isolated Levofloxacin-methicillin resistant Staphylococcus aureus (LVFX-r MRSA) strains (74 strains)2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID285278Susceptibility of penicillin-resistant Streptococcus pneumoniae 335 by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID285295Effect on 32 ug/ml ciprofloxacin-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID12187Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID164393Antibacterial activity was determined against Pseudomonas aeruginosa PAO1 strain after incubation at 37 degrees C for 18 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID66574Antibacterial activity was determined against clinically isolated vancomycin-B resistant enterococci (VRE) strains (10 strains)2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID285279Effect on 0.06 ug/ml DQ113-selected penicillin-resistant Streptococcus pneumoniae 335 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID12722Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID285285Effect on 0.06 ug/ml DQ113-selected penicillin-resistant Streptococcus pneumoniae 334 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID211824Mortality was determined after 150 mg/kg dose administered intravenously to 5-week old male mice at a speed of 0.2 mL/min counted on day 7 for total 5 mice2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID231325Ratio of total concentration in kidney to that of serum after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID285300Effect on 4 ug/ml levofloxacin-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID285304Effect on 0.5 ug/ml sitafloxacin-selected penicillin-resistant Streptococcus pneumoniae 218 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID285301Effect on 8 ug/ml ciprofloxacin-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID67078Antibacterial activity was determined against Enterococcus faecalis ATCC 19433 strain after incubation at 37 degrees C for 18 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID285287Effect on 1 ug/ml moxifloxacin-selected penicillin-resistant Streptococcus pneumoniae 334 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID12188Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID285282Effect on 16 ug/ml levofloxacin-selected penicillin-resistant Streptococcus pneumoniae 335 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID285296Susceptibility of penicillin-resistant Streptococcus pneumoniae 217 by by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID285302Susceptibility of penicillin-resistant Streptococcus pneumoniae 218 by by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID285298Effect on 0.5 ug/ml sitafloxacin-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID285292Effect on 0.5 ug/ml sitafloxacin-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID212506Toxicity was determined as presence of micronucleated reticulocytes (MNRET) in blood at 24 and 48 h after 150 mg/kg dose administered intravenously to 5-week old male mice; negative.2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID285280Effect on 0.5 ug/ml sitofloxacin-selected penicillin-resistant Streptococcus pneumoniae 335 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID231328Ratio of total concentration in serum to that of serum after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID66578Antibacterial activity was determined against clinically isolated vancomycin-B resistant enterococci (VRE) strains (10 strains)2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID211688Mortality was determined after 100 mg/kg dose administered intravenously to 5-week old male mice at a speed of 0.2 mL/min counted on day 7 for total 2 mice; NT= Not tested2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID285299Effect on 0.5 ug/ml moxifloxacin-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID12192Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID208611Antibacterial activity was determined against clinically isolated penicillin resistant Streptococcus pneumoniae (PRSP) strains (50 strains)2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID210029Antibacterial activity was determined against Streptococcus pneumoniae J-24 strain after incubation at 37 degrees C for 18 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID12291Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID209273Antibacterial activity was determined against Streptococcus pyogenes G-36 strain after incubation at 37 degrees C for 18 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID69933Antibacterial activity was determined against Escherichia coli NIHJ strain after incubation at 37 degrees C for 18 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID285297Effect on 0.03 ug/ml DQ113-selected penicillin-resistant Streptococcus pneumoniae 216 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID285310Susceptibility of drug-selected vancomycin-resistant Enterococcus species mutant by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID231327Ratio of total concentration in lung to that of serum after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID207483Antibacterial activity was determined against Staphylococcus aureus FDA 209-P strain after incubation at 37 degrees C for 18 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID285284Susceptibility of penicillin-resistant Streptococcus pneumoniae 334 by by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID285286Effect on 0.5 ug/ml sitafloxacin-selected penicillin-resistant Streptococcus pneumoniae 334 mutant after five passages assessed as susceptibility by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID66572Antibacterial activity was determined against clinically isolated vancomycin-A resistant enterococci (VRE) strains (33 strains)2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID285308Susceptibility of methicillin-sensitive/resistant Staphylococcus aureus single-step mutant by agar dilution method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
AID96072Antibacterial activity was determined against Klebsiella pneumoniae type II strain after incubation at 37 degrees C for 18 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID231326Ratio of total concentration in liver to that of serum after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID12292Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
AID12028Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		2.7130aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
gatifloxacin
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.		2.4220N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
penicillin g
Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.		2.0110penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		3.1150monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		7.4220glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
trovafloxacin
trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity. trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.		2.0110
arbekacin
arbekacin: structure given in first source. arbekacin : A kanamycin that is kanamycin B bearing an N-(2S)-4-amino-2-hydroxybutyryl group on the aminocyclitol ring.		2.0110aminoglycoside;
kanamycins		antibacterial agent;
antibacterial drug;
antimicrobial agent;
protein synthesis inhibitor
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		2.43209-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
moxifloxacin
Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.		2.4320aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
linezolid
[no description available]		2.0110acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
sitafloxacin
[no description available]		2.0310fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic
gemifloxacin
Gemifloxacin: A naphthyridine and fluoroquinolone derivative antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used for the treatment of community-acquired pneumonia and acute bacterial infections associated with chronic bronchitis.. gemifloxacin : A 1,4-dihydro-1,8-naphthyridine with a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a substituted pyrrolin-1-yl group at the 7-position.		2.01101,8-naphthyridine derivative;
fluoroquinolone antibiotic;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
topoisomerase IV inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Bacterial Infections, Gram-Positive
[description not available]		02.0310
Gram-Positive Bacterial Infections
Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.		02.0310
Disease, Pulmonary
[description not available]		02.0110
Infections, Staphylococcal
[description not available]		02.0110
Lung Diseases
Pathological processes involving any part of the LUNG.		02.0110
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		02.0110
Pneumonia, Pneumococcal
A febrile disease caused by STREPTOCOCCUS PNEUMONIAE.		02.0110
Bacterial Disease
[description not available]		02.0110
Bacterial Infections
Infections by bacteria, general or unspecified.		02.0110